Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SCL003
MIFTS: 48

Social Phobia

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Social Phobia

About this section

MalaCards integrated aliases for Social Phobia:

Name: Social Phobia 12 15
Phobic Anxiety Disorder 73
Phobic Disorders 44
Phobia, Social 73
Phobia Social 55

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:11257
ICD9CM 35 300.23
MeSH 44 D010698
NCIt 50 C34927
UMLS 73 C0031572
Sources

Summaries for Social Phobia

About this section
Disease Ontology : 12 A phobic disorder that involves social anxiety occurring only in specific public or social situations, interactions with others or being evaluated or scrutinized by other people.

MalaCards based summary : Social Phobia, also known as phobic anxiety disorder, is related to phobic disorder and agoraphobia. An important gene associated with Social Phobia is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Norepinephrine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, colon and amygdala, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Social Phobia

About this section

Diseases related to Social Phobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 phobic disorder 33.2 HTR1A MAOA SLC6A4
2 agoraphobia 30.5 HTR1A MAOA SLC6A4
3 sexual disorder 30.0 HTR1A PRL
4 depression 29.8 HTR1A HTR3A MAOA SLC6A4
5 borderline personality disorder 29.5 HTR1A MAOA SLC6A4
6 premature ejaculation 29.5 HTR1A HTR3A SLC6A4
7 bruxism 29.4 DRD2 SLC6A4
8 personality disorder 29.3 DRD2 HTR1A MAOA SLC6A4
9 drug dependence 29.3 DRD2 SLC6A4
10 anxiety 29.1 CCK HTR1A HTR3A MAOA SLC6A4
11 eating disorder 28.7 CCK DRD2 SLC6A4
12 panic disorder 28.7 CCK HTR1A HTR3A MAOA SLC6A4
13 mood disorder 28.3 DRD2 HTR1A MAOA SLC6A4
14 autism 28.2 DRD2 HTR1A MAOA SLC6A4
15 generalized anxiety disorder 28.1 DRD2 HTR1A HTR3A MAOA SLC6A4
16 obsessive-compulsive disorder 27.2 DRD2 HTR1A HTR3A MAOA PRL SLC6A4
17 major depressive disorder 26.5 DRD2 HTR1A HTR3A MAOA PRL SLC6A4
18 bipolar disorder 26.5 DRD2 HTR1A HTR3A MAOA PRL SLC6A4
19 alcohol dependence 26.1 CCK DRD2 HTR1A HTR3A MAOA SLC6A4
20 schizophrenia 25.9 CCK DRD2 HTR1A HTR3A MAOA PRL
21 avoidant personality disorder 10.6
22 atypical depressive disorder 10.4 MAOA SLC6A4
23 dysthymic disorder 10.4 MAOA SLC6A4
24 paraphilia disorder 10.4 MAOA PRL
25 paranoid schizophrenia 10.3 MAOA SLC6A4
26 endogenous depression 10.3 MAOA SLC6A4
27 psychosexual disorder 10.2 HTR1A SLC6A4
28 mutism 10.2
29 elective mutism 10.2
30 stereotypic movement disorder 10.2 CCK PRL
31 rumination disorder 10.2 HTR1A HTR3A
32 fibromyalgia 10.2 HTR3A SLC6A4
33 motion sickness 10.1 HTR1A HTR3A
34 aging 10.1
35 strabismus 10.0
36 phobia, specific 10.0
37 body dysmorphic disorder 10.0
38 separation anxiety disorder 10.0
39 bipolar i disorder 10.0 HTR1A SLC6A4
40 amnestic disorder 10.0 HTR1A HTR3A
41 functional gastric disease 10.0 CCK HTR3A
42 galactorrhea 10.0 DRD2 PRL
43 schizophreniform disorder 10.0 DRD2 PRL
44 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.0
45 stuttering 10.0
46 prolactin producing pituitary tumor 9.9 DRD2 PRL
47 functioning pituitary adenoma 9.9 DRD2 PRL
48 alcohol-induced mental disorder 9.9 DRD2 SLC6A4
49 kleptomania 9.9 HTR1A MAOA SLC6A4
50 peripartum cardiomyopathy 9.9 DRD2 PRL

Comorbidity relations with Social Phobia via Phenotypic Disease Network (PDN):


Anxiety Dysthymic Disorder

Graphical network of the top 20 diseases related to Social Phobia:



Diseases related to Social Phobia
Sources

Symptoms & Phenotypes for Social Phobia

About this section

GenomeRNAi Phenotypes related to Social Phobia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Social Phobia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.8 CCK DRD2 HTR1A HTR3A MAOA PRL
2 endocrine/exocrine gland MP:0005379 9.55 CCK DRD2 HTR3A PRL SLC6A4
3 homeostasis/metabolism MP:0005376 9.5 CCK DRD2 HTR1A HTR3A MAOA PRL
4 nervous system MP:0003631 9.17 CCK DRD2 HTR1A HTR3A MAOA PRL
Sources

Drugs & Therapeutics for Social Phobia

About this section

Drugs for Social Phobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
2
Citalopram Approved Phase 4,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
3
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
4
Ketamine Approved, Vet_approved Phase 4,Early Phase 1 6740-88-1 3821
5
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
6
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79617-96-2 68617
7
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68-41-7 401 6234
8
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
9
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
10
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
11
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
12 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
13
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
14
Propranolol Approved, Investigational Phase 4,Phase 2,Not Applicable 525-66-6 4946
15
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
16
Topiramate Approved Phase 4 97240-79-4 5284627
17
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
18
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
19
Acetylcholine Approved Phase 4 51-84-3 187
20 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
21 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
24 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Cholinergic Agents Phase 4,Phase 2,Phase 1,Not Applicable
33 Cholinergic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
34 Muscarinic Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
35 Parasympatholytics Phase 4,Phase 2,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Analgesics Phase 4,Phase 3,Early Phase 1,Not Applicable
38 Anesthetics Phase 4,Phase 1,Early Phase 1
39 Anesthetics, Dissociative Phase 4,Early Phase 1
40 Anesthetics, General Phase 4,Early Phase 1
41 Anesthetics, Intravenous Phase 4,Early Phase 1
42 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
43 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Early Phase 1
44 Serotonin 5-HT1 Receptor Agonists Phase 4,Not Applicable
45 Anticonvulsants Phase 4,Phase 2,Phase 3
46 GABA Agents Phase 4,Phase 1
47 GABA Modulators Phase 4,Phase 1
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3,Not Applicable
49 Venlafaxine Hydrochloride Phase 4,Phase 3,Not Applicable
50 Antipsychotic Agents Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 317)
# Name Status NCT ID Phase Drugs
1 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
2 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
3 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
4 Nefazodone in the Treatment of Social Phobia Completed NCT00231348 Phase 4 Nefazodone
5 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
6 Study To Evaluate The Effects Of Gabitrilâ„¢ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4 Gabitril
7 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4 Escitalopram
8 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
9 Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
10 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
11 RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
12 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
13 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
14 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
15 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
16 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
17 Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Recruiting NCT00182455 Phase 4 Topiramate;Placebo
18 Ketamine Infusion for Adolescent Depression and Anxiety Recruiting NCT02579928 Phase 4 Ketamine;Midazolam
19 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram
20 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Active, not recruiting NCT02294305 Phase 4 Vortioxetine;Placebo
21 Brief Intervention to Reduce Fear of Public Speaking Active, not recruiting NCT02790736 Phase 4 propranolol;Placebo
22 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
23 Guanfacine Extended Release and Mindfulness Skills Therapy Not yet recruiting NCT03258476 Phase 4 Guanfacine Extended Release;Placebo
24 A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder Terminated NCT03078270 Phase 4 botulinum toxin A
25 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
26 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
27 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
28 Residential Cognitive and Interpersonal Therapy for Social Phobia Completed NCT00326430 Phase 2, Phase 3
29 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
30 A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Completed NCT00564967 Phase 3
31 Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3 quetiapine
32 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
33 Social Anxiety Disorder Study Of Paroxetine Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
34 Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3 PH94B
35 Flushing in Social Anxiety Disorder on Seroquel Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
36 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo
37 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Completed NCT00074802 Phase 3 Paroxetine
38 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
39 Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder Completed NCT00238719 Phase 3 Venlafaxine ER
40 Long-term Study Of Paroxetine in Women and Men Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
41 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed NCT00114127 Phase 3 Duloxetine;Duloxetine;Placebo
42 St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) Completed NCT00118833 Phase 2, Phase 3 Hypericum perforatum (St. John's wort)
43 A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder Completed NCT01654510 Phase 2, Phase 3
44 A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder Completed NCT00411398 Phase 3 Namenda/Memantine
45 Treatment for Anxiety in Children Completed NCT00000389 Phase 3 Fluvoxamine
46 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
47 Child and Adolescent Anxiety Disorders (CAMS) Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
48 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
49 Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00320528 Phase 3 atomoxetine
50 Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder Recruiting NCT03017508 Phase 2, Phase 3 BHV-0223;Placebo

Search NIH Clinical Center for Social Phobia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: phobic disorders

Sources

Genetic Tests for Social Phobia

About this section
Sources

Anatomical Context for Social Phobia

About this section

MalaCards organs/tissues related to Social Phobia:

41
Brain, Colon, Amygdala, Testes, Heart, Cortex, Pituitary
Sources

Publications for Social Phobia

About this section

Articles related to Social Phobia:

(show top 50) (show all 620)
# Title Authors Year
1
Psychometric Evaluation of the Social Phobia Inventory and the Mini-Social Phobia Inventory in a Swedish University Student Sample. ( 29375026 )
2018
2
Optimal Cut Points for Remission and Response for the German Version of the Social Phobia Anxiety Inventory (SPAI). ( 29862918 )
2018
3
Avoidant personality disorder and social phobia: Does mindreading make the difference? ( 29096207 )
2018
4
Identifying sub-categories of social fears using an alternative factor analytic structure of the Social Phobia and Anxiety Inventory. ( 28236783 )
2017
5
Confirmatory Factor Analysis of the Combined Social Phobia Scale and Social Interaction Anxiety Scale: Support for a Bifactor Model. ( 28210232 )
2017
6
Social phobia, depression and eating disorders during middle adolescence: longitudinal associations and treatment seeking. ( 28868945 )
2017
7
Comorbidity of schizophrenia and social phobia - impact on quality of life, hope, and personality traits: a cross sectional study. ( 28831256 )
2017
8
Collaborative care for panic disorder, generalised anxiety disorder and social phobia in general practice: study protocol for three cluster-randomised, superiority trials. ( 28814317 )
2017
9
Mini - social phobia inventory (mini-SPIN): psychometric properties and population based norms of the German version. ( 29178857 )
2017
10
Daily fluctuation of emotions and memories thereof: Design and methods of an experience sampling study of major depression, social phobia, and controls. ( 28948700 )
2017
11
Depression and social phobia in essential tremor and Parkinson's disease. ( 28948077 )
2017
12
Social Phobia: The Role of In-Situation Safety Behaviors in Maintaining Anxiety and Negative Beliefs - Republished Article. ( 27816079 )
2016
13
Autonomic markers associated with generalized social phobia symptoms: heart rate variability and salivary alpha-amylase. ( 27892761 )
2016
14
Selective Mutism: The Fraternal Twin of Childhood Social Phobia. ( 27089281 )
2016
15
Virtual reality exposure using three-dimensional images for the treatment of social phobia. ( 26561376 )
2016
16
The effect of Interaction Anxiousness Scale and Brief Social Phobia Scale for screening social anxiety disorder in college students: a study on discriminative validity. ( 27935389 )
2016
17
Social Phobia Is Associated with Delayed Onset of Chickenpox, Measles, and Mumps Infections. ( 28082921 )
2016
18
Examination of the Correlation Between Internet Addiction and Social Phobia in Adolescents. ( 27561297 )
2016
19
No effects of psychosocial stress on memory retrieval in non-treated young students with Generalized Social Phobia. ( 27464065 )
2016
20
Attentional mechanisms of social perception are biased in social phobia. ( 27131909 )
2016
21
Factor solutions of the Social Phobia Scale (SPS) and the Social Interaction Anxiety Scale (SIAS) in a Swedish population. ( 27894213 )
2016
22
Psychometric properties of the mini-social phobia inventory (Mini-SPIN) in a large online treatment-seeking sample. ( 27046641 )
2016
23
Assimilation, reflexivity, and therapist responsiveness in group psychotherapy for social phobia: A case study. ( 27092848 )
2016
24
Hypochondriasis Differs From Panic Disorder and Social Phobia: Specific Processes Identified Within Patient Groups. ( 27805984 )
2016
25
Retracted: Combined Case of Blood-Injury-Injection Phobia and Social Phobia: Behavior Therapy Management and Effectiveness through Tilt Test. ( 27722005 )
2016
26
Community-Based Validation of the Social Phobia Screener (SOPHS). ( 26939801 )
2016
27
Correction: The Neuroanatomical Basis of Panic Disorder and Social Phobia in Schizophrenia: A Voxel Based Morphometric Study. ( 25906143 )
2015
28
An experimental investigation of the functional relationship between social phobia and cigarette smoking. ( 25576952 )
2015
29
Social Phobia and Educational and Interpersonal Impairments in Adolescence: A Prospective Study. ( 26514560 )
2015
30
Behavioral treatment of social phobia in youth: Does parent education training improve the outcome? ( 25727679 )
2015
31
Correction: Avoidant Personality Disorder versus Social Phobia: The Significance of Childhood Neglect. ( 25978045 )
2015
32
Comparison of automatical thoughts among generalized anxiety disorder, major depressive disorder and generalized social phobia patients. ( 26241548 )
2015
33
Attachment styles in patients with avoidant personality disorder compared with social phobia. ( 26332087 )
2015
34
Reprint of: Social phobia and other psychiatric problems in children with strabismus. ( 26049893 )
2015
35
Intensive Group-Based CBT for Child Social Phobia: A Pilot Study. ( 25892171 )
2015
36
Social anxiety disorders in clinical practice: differentiating social phobia from avoidant personality disorder. ( 26129819 )
2015
37
Latent dimensions of social anxiety disorder: A re-evaluation of the Social Phobia Inventory (SPIN). ( 26454660 )
2015
38
Social phobia and quality of life in morbidly obese patients before and after bariatric surgery. ( 25863007 )
2015
39
Developmental Differences in Functioning in Youth With Social Phobia. ( 26630122 )
2015
40
Short-term Dynamic Psychotherapy versus Sertraline in Treatment of Social Phobia. ( 26288643 )
2015
41
The neuroanatomical basis of panic disorder and social phobia in schizophrenia: a voxel based morphometric study. ( 25774979 )
2015
42
Avoidant Personality Disorder versus Social Phobia: The Significance of Childhood Neglect. ( 25815817 )
2015
43
Comparing Short Forms of the Social Interaction Anxiety Scale and the Social Phobia Scale. ( 24932648 )
2014
44
Subliminal cues bias perception of facial affect in patients with social phobia: evidence for enhanced unconscious threat processing. ( 25136307 )
2014
45
Hypnosis aided fixed role therapy for social phobia: a case report. ( 24938079 )
2014
46
Social phobia in Parkinson's disease: Prevalence and risk factors. ( 24926195 )
2014
47
Bruxism and oral parafunctional hyperactivity in social phobia outpatients. ( 25238249 )
2014
48
Randomized Controlled Trial of Cognitive Behavioral Therapy and Acceptance and Commitment Therapy for Social Phobia: Outcomes and Moderators. ( 24999670 )
2014
49
Social Phobia symptoms across the adult lifespan. ( 25043319 )
2014
50
The contribution of the therapist's competence in the treatment of adolescents with generalized social phobia. ( 25340895 )
2014
Sources

Variations for Social Phobia

About this section
Sources

Expression for Social Phobia

About this section
Search GEO for disease gene expression data for Social Phobia.
Sources

Pathways for Social Phobia

About this section

Pathways related to Social Phobia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.67 HTR1A HTR3A MAOA SLC6A4
2
Serotonergic synapse 37
11.31 HTR1A HTR3A MAOA SLC6A4
3
Monoamine Transport 1
Show member pathways
 10.96 MAOA SLC6A4
4
Neurotransmitter Clearance In The Synaptic Cleft 66
Show member pathways
 10.67 MAOA SLC6A4
5
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 61
10.37 HTR1A HTR3A MAOA SLC6A4
Sources

GO Terms for Social Phobia

About this section

Cellular components related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.13 CCK DRD2 HTR1A
2 axon GO:0030424 8.8 CCK DRD2 HTR3A

Biological processes related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 excitatory postsynaptic potential GO:0060079 9.26 DRD2 HTR3A
2 response to cocaine GO:0042220 9.16 DRD2 HTR3A
3 behavioral fear response GO:0001662 8.96 CCK HTR1A
4 vasoconstriction GO:0042310 8.62 HTR1A SLC6A4

Molecular functions related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 8.62 HTR1A HTR3A
Sources

Sources for Social Phobia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....